An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer

Xu, J; Gao, Y; Luan, XT; Li, K; Wang, J; Dai, YL; Kang, MY; Lu, C; Zhang, MH; Lu, CX; Kang, Y; Xu, CJ

Kang, Y; Xu, CJ (通讯作者)，Fudan Univ, Obstet & Gynecol Hosp, Shanghai 200011, Peoples R China.;Kang, Y; Xu, CJ (通讯作者)，Shanghai Key Lab Female Reprod Endocrine Related, Shanghai 200011, Peoples R China.;Xu, CJ (通讯作者)，Fudan Univ, Shanghai Med Coll, Obstet & Gynecol, Shanghai, Peoples R China.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022; 89 (5): 683

Abstract

Background Although the use of PARP inhibitor has received considerable amount of attention in ovarian cancer, PARP inhibitor resistance still emerges......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索